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Abstract 
The transfusion of blood products is an essential and also a common therapeutic procedure used in veterinary medicine. 
Because blood transfusion is not a completely harmless therapeutic procedure, its usage requires a good amount of 
knowledge about the possible adverse effects and complications that may occur during this process. This kind of data is 
exactly what the present study brings to doctors attention, being based upon the management of various forms of 
transfusions reactions in canines which were given whole blood, erythrocyte concentrate (EC) or blood plasma (P). The 
main objectives were preventing, monitoring and treatment of this reaction type. The clinics included in this study 
reported multiple forms of transfusion reactions in canine patients, such as: severe tachycardia (no=5); passing 
hyperthermia (40°C) (no=5); emesis and melaena during transfusion (no=3); myoclonic head seizures and bruxism 
(no=1); delayed hemolytic anemia (AHI) (no=1); TRALI type respiratory syndrome (no=1). In most cases, these 
symptoms subsided after a few minutes from transfusion or stopped completely, except the last two cases, which presented 
severe reactions, without any response to treatment and resulting in death. This kind of complications resulted due to 
AHI condition in a patient with chronic renal failure (the diagnosis was based on pollakiuria, haematuria and 
BUN/creatinine ratio of 28.4) and the evolution of TRALI respiratory syndrome in another patient with malignant 
multicenter lymphoma (cytologically confirmed). The AHI type of post transfusion reaction diagnosis and management 
was done by monitoring the decreasing oscillations of the whole blood mass, after 3 transfusions with whole blood. The 
TRALI syndrome (Transfusion-Related Acute Lung Injury) diagnosis was based upon cytological examination and later, 
necropsy. 
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Introduction 
Transfusion adverse reactions are the most common complications after therapy with blood 
products, and in humans, they occur at least once in one hundred cases (Delaney et al., 2016; 
Ognean, 2017). Similar reactions with those encountered in humans have been frequently reported 
in pets, without a correct diagnosis and treatment in most of the cases. These kinds of reactions are 
commonly caused by transfusion incompatibility and sometimes by inappropriate storage or 
administration of blood products. The majority of the adverse reactions occur during the 
transfusion process or right after it and they present acute hemolytic, anaphylactic or allergic 
reactions. Apart from these evident reactions, there are types of complications that cannot be 
immediately identified, such as: delayed hemolytic reaction, immune and non-immune reactions, 
hypothermia, citrate intoxication or heart failure (Abrams-Ogg, 2000; Kohn et al., 2000; 
Hohenhaus, 2006; Ognean, 2017).  
Among the principles that stand upon prevention and management of adverse reactions, 
we mention selection of the best compatible donor patient, proper storage and handling of blood 
products, patient monitoring and care during transfusion process, immediate stopping of 
transfusion when adverse reactions occur, immediate treatment of allergic or anaphylactic reactions 
with antihistaminic or cortisone products; adding adrenergic and antipyretic medication to the 
treatment protocol in case of fever and intravenous use of calcium in case of citrate intoxication 
symptoms. 
 




Material and methods 
The present paper was designed to present the management of complications and 
transfusion reactions occurred in canine patients transfused with whole blood, erythrocytes 
concentrate (EC) or plasma (P) in some veterinary clinics from Transylvania. The major purpose 
of this research was to evaluate the efficiency of  some preventive methods and the adverse 
transfusion reactions treatment in dogs from clinics and veterinary practices.  
The evaluation process was carried out by 3 clinics and 4 veterinary private practices, 
which reported 16 forms of complications/transfusion reactions, such as: severe tachycardia - 5 
cases; passing hyperthermia (40°C) - 5 cases; emesis and/or melaena during transfusion - 3 cases; 
myoclonic head seizures and bruxism - one case; delayed hemolytic anemia (AHI) - one case; 
TRALI (Transfusion-Related Acute Lung Injury) type respiratory syndrome - one case. Patients 
evaluation and decision making of blood transfusion was based upon the correlation between the 
clinical, haematological and biochemical examination, with automated or semi automated 
hematology analyzers (Abacus Junior Vet and Idexx QBC Vetautoread) and automated analyzer 
for clinical chemistry (Arkray Spotchem EZ-SP-4430 Refurbished and MINDRAY BA-88ª). In 
some cases of severe illness, the diagnosis confirmation was carried out at SinevoVet or other 
diagnostic centers. 
The transfusion of blood products was made, in most of the cases, after establishing the 
donor-patient compatibility with blood type tests (Rapid Vet®H-DMS Laboratories and Rapid 
DMEVET-Alvedia) and/or Crossmatch. We observed that 4 of the patients were transfused without 
compatibility evaluation, the reason invoked being the emergency of the procedure and the absence 
of transfusion risk. The blood products were administered exclusively intravenously (cephalic vein, 
saphenous vein and jugular vein), by using closed circuit IV (intravenous) set tubing and catheters, 
which were previously selected according to patients size; in some cases, blood filters were used. 
The blood product dose was set after the correlation between body weight and anemia 
severity and erythrocytes mass values (RBC, HCT and Hb). Some of the doctors evaluated even 
the lost blood volume, using the well known formula: “Given blood volume (mL) = 80 x kg x 
(desired Ht - receiving patients Ht)/donors Ht” (Abrams-Ogg, 2000). Taking into account the 
aforementioned factors, the calculated doses for whole blood and EC varied between 10 and 20 
mL/kg. Two of the patients were treated with CE, diluted with saline (3:1), for the administration 
ease. The transfusion rate, in the first 30 minutes was of 0.3-3 mL/kg/h, upping the dose to 10 
mL/kg/h. Moreover, during the entire transfusion process, some of the basic physiological 
parameters were monitored, namely respiratory rate and internal temperature in every patient. 
The values obtained from blood chemistry tests were statically and graphically analyzed, 
by using GraphPad Instat, Excel, Prism 4th version and OriginLab 8.5 programs. Because most 
complications subsided after a few minutes of pausing the transfusion or completely stopped, we 
continue with two exceptions, resulting due to AHI and TRALI type transfusion reactions, 
characterized by severe evolution, unfavourable therapeutic response and patients death. 
AHI type transfusion reaction was observed in a patient (6 years old, unneutered, female), 
suffering from chronic renal failure, with BUN (71 mg/dl) and creatinine values (28.4 mg/dl), 
complicated with severe non regenerative chronic anemia, low values of RBC (1.46 T/L), HCT 
(6.3%), Hb (2.1 mg/dl) and VEM (42mg/dl), critical clinical status and unfavourable prognosis. 
Based on the severity of the anemia, the patient received an immediate first transfusion with whole 
blood (one unit - 450 mg, on CPAD1), collected from a donor (male, half-breed, vaccinated and 
dewormed), without any blood compatibility tests done prior. This patient received in previous 
other 2 compatible transfusions, a unit of whole blood, in order to correct the mild increase of 




erythrocyte indices, 24 hours after transfusion, and to correct the decreasing trend of these values 
in the next 30 days. 
TRALI respiratory syndrome was diagnosed in a patient (male, Rottweiler breed, 7 years 
old, DEA 1.1 positive), suffering from a multicenter lymphoma, cythologically confirmed. This 
patient was undergoing treatment for arthritis and renal failure 1st grade, and it was brought to the 
clinic because he presented loss of appetite, listlessness, hypersalivation, mass weight loss and 
dysphagia. Clinical examination revealed fever, hypertrophy of the prescapular and popliteus 
lymph nodes and tonsils hypertrophy. Blood tests were performed and biopsy was performed form 
prescapular and popliteal lymph nodes, in order to establish a diagnosis certainty. Based upon the 
conducted tests and the obtained results, a complex therapeutic protocol was elaborated, focusing 
on chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone), symptomatic 
treatment and whole blood transfusion. Unfortunately, this patient developed an extremely severe 
form of TRALI reaction, 72 hours after the second transfusion (with one whole blood unit), which 
was followed by increased values of Ht (19%) and Hb (6,9 mg/dl) and finally, a third transfusion 
with whole blood was necessary. 
 
Results and disscussions 
During the whole blood, EC and P transfusions, in all the canine patients subjected to this 
study, no severe adverse reactions, such as acute intravascular hemolysis or anaphylactic shock 
were observed. However, some mild intensity transfusional reactions were recorded in 5 cases, 
namely the increasing pulse and heart rate. The main measure chosen for subsidising these 
complications was to interrupt, even for a few minutes the transfusion, until the heart rate 
normalized - in 3 cases and in another 2 cases - the solution was to completely stop the transfusion. 
We have also noticed an increased sensitivity in peripheral veins, punctured for administration of 
whole blood and EC, characterized by patients agitation, without causing phlebitis or 
thrombophlebitis. In case of plasma administration, no side effects were registered. In 5 of the 
cases, temporary transfusion reactions were observed, such as hyperthermia (40°C), which 
occurred 24 hours after the transfusion, but without any complications. 
The emesis and melaena symptoms during transfusion, in 3 patients with parvovirosis, 
were considered to be complications of this intensive treatment procedure. Another post transfusion 
reaction consisting of myoclonic head seizures and bruxism was present in one patient, aged 3 
months, after the second transfusion with whole blood. According to this patient's anamnesis, we 
must recall three surgical procedures, namely an osteosynthesis for treating a fractured injury 
resulted after a car accident and two enterectomy procedures after an episode of recurrent intestinal 
volvulus. Additionally, the patient also developed a parasitic infestation which hastened its death. 
As expected, important increases in serum total bilirubin were reported in most patients, exceeding 
the maximum allowable limits (3.6 mmol/L) only in the first 24 hours after whole blood, EC and 
even P transfusion, but these values normalized shortly after.  
Regarding  the patient with AHI, we mention that 24 hours after the first transfusion with 
one unit of whole blood, it presented mild increases of the erythrocyte indices, which determined 
the requirement of another two transfusions, each of them performed with one unit of whole blood, 
during two months. The post- transfusion data, presented in table 1, revealed that RBC values 
increased the following day to 2.33 T/L and the HCT values to 13.5%; on the third day after 
transfusion we observed a decrease in values to 1.81 T/L, for RBC and 10.2%, for HCT. The 
evolution of erythrocyte indices included mild increases of RBC (4.7 T/L) and HCT (27.2%) within 
the 4-30 days interval, followed by an important decrease of these values, two months post 
transfusion, when the patient health worsened considerably. Based on this evolution, we consider 




that the investigated patient developed a delayed hemolytic reaction, because the transfusion with 
whole blood was done without testing the donor-patient compatibility prior to transfusion and it 
was not followed by an important increase of erythrocyte indices, which may indicate a possible 
rejection of the administered red blood cells. Furthermore, the data presented in table 1 indicate 
that after the last transfusion, the decreasing trend of erythrocyte values amplified and the low 
values of RBC (1.55 T/L) and HCT (11.2%) were associated with a worsening health state. Under 
these conditions, intensive care measures were taken, with hydration intravenous (IV) infusion and 
glucocorticoids to lower creatinine levels. Furthermore, it is noteworthy to mention the severe 
chronic renal failure evolution, which also led to important changes in blood leukocyte and 
biochemical indices. Therefore, we can only mention the very high values of leukocytosis (21-42 
G/L) and granulocytosis (78.8-84.4%), maintained in the first 30 days of the survival period.  
Equally important were metabolic indices changes, such as blood sugar fluctuations (101-
228 mg / dL), associated with increased values of BUN (40-155 mg / dL) and creatinine (2.5-11.2 
mg / dL) (Table 1). Finally, all the undergoing measures proved to be inefficient, because the 
patient went into cardio respiratory arrest and died. 
 
Table 1.  
Haemato-biochemical parameters evolution in a patient with AHI condition 
 
Legend: RBC-Red blood cells; HCT-Haematocrit; HGB-Haemoglobin; MCV-Mean corpuscular volume; MCH-Mean 
corpuscular hemoglobin; MCHC-Mean corpuscular hemoglobin concentration; RDW-Red cell distribution width; 
WBC-White blood cells; GR-Granulocytes; LYM-Lympocytes; MONO-Monocytes; PLT-Platelets; Glu-Glucose; 
BUN- Blood urea nitrogen; Tbili.-Total bilirubin; Ca-Calcium; Tprot.- Total serum protein; Alb.- Albumin; ALT-
Alanine aminotransferase; ALP-Alkaline phosphatase; Crea.-Creatinine. 
 
Regarding TRALI respiratory syndrome evolution, we have observed that this post 
transfusion reaction manifested in an extremely severe form, although the patient presented slight 
P a r a m e t e r / D a y R e f e r e n c e s 1 2 3 4 5 6 8 1 2 3 3 0 0 660 
 
RBC (T/L) 5-7.9 1.49 2.33 1.81 2.08 2.2 2.5 3.18 4.8 4.7 1.55 
HCT (%) 35-57 6.3 13.5 10.2 11.02 11.9 13.7 17.8 21.7 27.2 11.2 
HGB (g/dL) 12-19 2.1 4.7 3.7 3.9 4 4.6 6.2 6.7 9.6 4.4 
MCV (µm3) 66-77 42 58 56 54 54 55 56 53 58 72 
MCH (pg) 21-26.2 13.9 20.1 20.5 18.9 18.4 18.3 19.5 16.4 20.5 28.2 
MCHC (g/dL) 32-36.3 32.9 34.6 36.5 34.8 34 33.4 34.9 30.9 35.5 38.9 
RDW (%) 14-17 17.9 22.4 22.2 24.7 25.6 24.4 22.5 23.4 21.9 13 
WBC (G/L) 5-14.1 33.8 33.9 30.1 25.4 28.9 39.6 - 42 29.5 9 
GR(%) 58-88 71.7 84.2 84.4 82.1 83 80.6 - 78.8 84.2 87.4 
LYM (%) 8-21 21 10.5 10.5 14 13.2 14 - 13.4 11.3 8.2 
MONO (%) 2-10 7.3 5.3 5.1 3.9 3.8 5.4 - 7.8 4.5 4.4 
PLT (x109/L) 211-621 280 355 250 460 697 675 642 571 616 425 
Glu. (mg/dL) 76-119 76-119 228 114 152 101 118 141 115 115 144 
BUN (mg/dL) 8-28 8-28 71 55 57 45 40 49 53 43 155 
Tbili. (mg/dL) 0-0.3 0-0.3 0.3 0.5 - - 1.1 1.2 1.0 0.9 - 
Ca (mg/dL) 9.1-11.7 9.1-11 10.5 - - - - - 12.7 - - 
Tprot. (g/dL) 6.0-7.5 5.4-7.5 7.9 8.1 8.6 8.6 9 8.5 8.9 7.3 6.3 
Alb. (g/dL) 2.3-3.1 2.3-3.1 2.1 2.2 - - - - 2.6 - 1.9 
ALT (UI/L) 22-47 10-109 26 - 11 11 15 8 6 6 118 
ALP (UI/L) 1-114 1-114 108 146 204 190 224 218 216 190 77 
Crea. (mg/dL) 0.5-1.7 0.5-1.7 2.5 2.9 4.7 4.7 4.4 3.9 3.1 2.5 11.2 




improvements of the health state and hematologic parameters right after the transfusion with whole 
blood (Table 2). 72 hours after the second transfusion, with one unit of whole blood, the values of 
HTC (19%) and Hb (6,9 mg/dl) decreased (Table 2), which determined the transfusion of another 
unit of whole blood. 24 hours after the last transfusion, the health state worsened, the patient 
presenting emesis, severe dyspnea, fever, pale mucosa, tachycardia, decubitus position. Under 
these conditions, the emergency therapeutic protocol was supplemented with oxygen therapy, 
intravenous rehydration, vitamins, furosemid, antacids, antiemetics, and liver protection. Despite 
the implemented measures, the onset of decompensated shock was inevitable, with cardio-
circulatory arrest and patient death.  
The necropsy examination emphasized specific changes for TRALI syndrome, due to the 
presence of a foamy fluid in the trachea and in the entire bronchial tree, and dense formations the 
size of a millet, onto the entire surface of the lung. 
Most of the adverse transfusion reactions reported in this study are undesirable metabolic 
or immunological disturbances that may occur frequently during or after administration of blood 
products (Mcdevitt et al., 2011; Ognean, 2017). Moreover, they were of mild intensity and did not 
present any threat to the patients life. 
 
Table 2.  
Main haematological parameters evolution in a patient with TRALI syndrome 
 









Prior Post Prior Post Prior Post 
HTC (%) 21.5 21.9 20.8 24.3 19 23.2 37-55 
HGB (g/dL) 7 7.9 6.9 8.3 6.9 8.3 12-18 
WBC (G/L) 26 26.7 17.7 16.1 24.1 11.5 6-16.9 
GR (G/L) 25.5 25.1 16.3 14.1 22.7 7.9 3.3-12 
PLT (x109/L) 476 323 547 694 272 170 175-500 
Legend: HCT-Haematocrit; HGB-Haemoglobin; WBC-White blood cells; GR-Granulocytes; PLT-Platelets. 
 
The early administration of citrate, in an weakened patient, with an underlying condition 
of hypocalcemia, can result in the so called citrate intoxication (Lucas et al., 2004; Ognean, 2017); 
therein, we can explain the existence of myoclonic seizures and bruxism in one case. Other signs 
that can occur in these situations are tetany, hyperreflexia, epileptic form seizures, laryngeal spasms 
and even respiratory arrest (Giger et al., 1990). None of the patients presented any clinical signs of 
an acute hemolytic reaction. 
Generally, in the case of an acute hemolytic reaction, serum and urinary levels of 
hemoglobin increase in a matter of minutes after transfusion and the incompatible cells are removed 
from the circulatory system flow in less than 2 hours (Capon et al., 1995). Concerning the 
investigated patients included in this study, the post transfusion decrease of the total serum bilirubin 
levels sustained the positive evolution and not at all the onset of intravascular hemolysis, which 
had to be represented by hyperbilirubinemia (Weingart et al., 2004). The existence of emesis and 
melaena symptoms in 3 cases, could be attributed to parvovirosis and not to transfusion 
complications, although some authors claim that acute hemolytic reaction may go undetected or 
even falsely attributed to an underlying disease (Kessler et al., 2010). Hyperthermia presented by 




some patients receiving compatible blood, was due to the platelets or leukocytes amount brought 
by the administered blood. We mention that the non hemolytic fever is frequently associated with 
increased anti leukocytes antibodies to receptors. Moreover, one analysis based upon 348 
transfusion cases in dogs at the Berlin small animals clinic described the evolution of some 
transfusion reactions caused by the administration of CE, in 4 patients and the administration of  P 
in 2 patients, these aspects representing only 1.7% of the cases (Kohn et al., 2000). Reitemeyer et 
al. (2000) identified 2.2% of temporary transfusion reactions, during the procedure or immediately 
after the administration of red blood cells products in 186 dog patients. In general, the frequency 
of transfusion reactions, detected in this study, as well as by other researchers in the field is 
decreased, these being controlled by pre-transfusion testing of partner compatibility. On the other 
hand, we mention that only a small percentage of patients needed to repeat the transfusion with one 
of the blood products, which means that the number of previously sensitized dogs that had the 
opportunity to show an undesirable post-transfusion reaction was low. However, special attention 
should be paid to the identification of compatible blood when repeating the transfusion in any 
canine patient (Ognean, 2015). Concerning the evolution of the delayed hemolytic reaction, we 
remind that the symptoms have developed only after 9 days from the first incompatible transfusion, 
linked with increased levels of antibodies. Such a transfusion incompatibility can be caused by red 
blood cells bearing DEA 3, 5 and 7 antigens observed with a frequency of 10% in dogs that are 
DEA 3 negative and 20% in dogs that are DEA 5 negative (Ognean, 2017). Furthermore, AHI type 
reactions have been reported in DEA 7 negative dogs, after transfusion with DEA 7 positive blood 
(Ognean, 2017). It is also important to highlight the general tendency of labeling any undesirable 
effect of blood products transfusion as an immunological or non immunological reaction, with 
immediate response or later onset. In this regard, a major importance must be attributed to 
preventive measures designed to decrease the risk of developing any post transfusion reactions, 
with closer monitoring of the donor, the conditions in which the blood is collected, prepared, stored 
and administered. 
It is well known that the most worrying form of hemolytic transfusion reaction is the acute 
one, observed in canine patients DEA 1.1 negative that received DEA 1.1 positive blood, that were 
sensitized prior with red blood cells carrying DEA 1.1 antigen. The symptoms in this acute 
hemolytic reaction are fever, tachycardia, dyspnea, muscular tremor, emesis, apathy, low levels of 
hemoglobin and hemoglobinuria. As opposed to the acute form, the delayed hemolytic reaction has 
an extravascular form, with similar symptoms, but not with the same severity. This kind of reaction 
may occur from day two until the 21th day after transfusion. 
TRALI syndrome is one of the most severe forms of post transfusion reactions, due to its 
high rate of morbidity and mortality (Kopko et al., 1999; Toy et al., 2005). Confusions may 
sometimes appear because this syndrome has been known under different names, such as 
pulmonary hypersensitivity reaction, allergic pulmonary oedema, non cardiogenic oedema. In 
addition to this, it is unanimously accepted that this pathological entity is still hard to recognize, 
because it is not yet completely understood and described, due to diagnostic errors and due to lack 
of awareness about its importance (http://www.mymed.ro/injuria-pulmonara-acuta-post-
transfuzionala-trali.html). 
Regarding the evolution of the patients subjected to the present study, we regard the 
TRALI syndrome as the main factor that caused the patient death. The early onset of pulmonary 
symptoms, occurring during the transfusion, followed by late symptoms after transfusion (dyspnea, 
cyanosis, fever) described a characteristic clinical picture of this respiratory syndrome. This was 
well argued by morphopathological changes, focused on the predominance of tracheal and 
bronchial infiltrate. It should be noted, however, that the patient did not show symptoms of Acute 




Pulmonary Injury prior to transfusion. Another observation that could support the existence of 
TRALI in this patient is the persistence of thrombocytosis (Kohn et al., 2006). Platelets are thought 
to secrete numerous proinflammatory factors, often involved in the mechanism of TRALI 
syndrome, such as chemokines, which attract and activate neutrophils causing endothelial layer 
permeability. (Toy et al., 2005; Marik et al., 2008). 
 
Conclusions 
Most of the reported transfusion  reactions had a minor clinical impact and ensured a high 
level of recovery of the transfused patients, which was also supported by the implementation of 
adequate measures for the preparation and monitoring the transfusion therapy. However, we also 
encountered severe forms of transfusion reactions, which progressively worsened, ending with the 
patients death. In this regard, we attributed major clinical interest to delayed hemolytic anemia and 
TRALI respiratory syndrome, which caused serious complications in two patients, transfused 3 
times with whole blood, as palliative treatment in a severe form of chronic renal failure and 
malignant lymphoma, respectively. We consider that the patient with chronic renal failure 
developed an AHI-type transfusion reaction, because  it was transfused with large volumes of  
whole blood, without prior testing of patient-donor compatibility, which did not cause a rapid 
increase in erythrocyte indices, but their significant decrease in the first three days, with a slight 
remission at 30 days, followed by a decreasing trend. The results of the three blood transfusions 
indicated a possible rejection of red blood cells administered to this patient. The evolution of 
TRALI syndrome in a patient suffering from malignant lymphoma was based on the major risk 
conferred by repeated transfusions and the relevant changes detected at necropsy. 
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